The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss treatments, retatrutide appears to offer a more substantial decrease in body weight and improve metabolic markers,… Read More